Market Overview

Celgene Higher Off Positive Phase II Sunbeam Trial Of Oral Ozanimod

Related CELG
Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises
Prothena Plummets 60% After Lead Drug Fails Phase 2 Trial
We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers (Seeking Alpha)

Celgene Corporation (NASDAQ: CELG) shares are trading higher by $2.00 at $120.66 in Friday's session. The catalyst for the rally is a Phase II study of Oral Ozanimod with relapsing MS meeting its primary endpoint in reducing ARR, measured endpoints.

After a higher open, it had a brief retreat but found found support just under above Thursday's close ($118.66), only reaching $118.81 before continuing its move higher.

So far, the ensuing rally has cleared the pair of highs from Wednesday ($120.63) and Thursday ($120.77), reaching $120.90. If the rally continues, the next resistance daily resistance point comes in at its January 19 high of $121.59.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (CELG)

View Comments and Join the Discussion!